{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:46:40Z","timestamp":1789728400406,"version":"4.0.1"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["1698\/15"],"award-info":[{"award-number":["1698\/15"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jad.2017.04.068","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T05:30:18Z","timestamp":1493443818000},"page":"217-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis"],"prefix":"10.1016","volume":"218","author":[{"given":"Michael A.","family":"Sugarman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Huppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2017.04.068_bib1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","article-title":"The cost of dichotomising continuous variables","volume":"332","author":"Altman","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2017.04.068_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000346144","article-title":"Systematic review of blinding assessment in randomized controlled trials in schizophrenia and affective disorders 2000\u20132010","volume":"82","author":"Baethge","year":"2013","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2017.04.068_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.175.2.120","article-title":"Paroxetine in social phobia\/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine study group","volume":"175","author":"Baldwin","year":"1999","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1176\/ajp.155.1.36","article-title":"Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder","volume":"155","author":"Ballenger","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib5","first-page":"75","article-title":"The development of a clinician-administered PTSD scale","volume":"8","author":"Blake","year":"1995","journal-title":"J. Trauma Stress"},{"key":"10.1016\/j.jad.2017.04.068_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/PSY.0b013e318148c19a","article-title":"Exercise and pharmacotherapy in the treatment of major depressive disorder","volume":"69","author":"Blumenthal","year":"2007","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.jad.2017.04.068_bib7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.283.14.1837","article-title":"Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial","volume":"283","author":"Brady","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2017.04.068_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1037\/0021-843X.110.4.585","article-title":"Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample","volume":"110","author":"Brown","year":"2001","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.jad.2017.04.068_bib9","series-title":"Guidance for Industry: Guidelines for the Clinical Evaluation of Antidepressant Drugs","author":"Center for Drug Evaluation and Research","year":"1977"},{"key":"10.1016\/j.jad.2017.04.068_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1017\/S0033291705006124","article-title":"Strategy implementation in obsessive-compulsive disorder and trichotillomania","volume":"36","author":"Chamberlain","year":"2006","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2017.04.068_bib11","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.cct.2011.04.006","article-title":"Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials","volume":"32","author":"Chen","year":"2011","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.jad.2017.04.068_bib12","first-page":"279","article-title":"Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder","volume":"26","author":"Chouinard","year":"1990","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2017.04.068_bib13","series-title":"Cognitive-Behavioral Therapy for OCD","author":"Clark","year":"2004"},{"key":"10.1016\/j.jad.2017.04.068_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0005-7967(02)00044-X","article-title":"\"Not just right experiences\": perfectionism, obsessive-compulsive features and general psychopathology","volume":"41","author":"Coles","year":"2003","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.jad.2017.04.068_bib15","series-title":"The Handbook of Research Synthesis and Meta-Analysis","author":"Cooper","year":"2009"},{"key":"10.1016\/j.jad.2017.04.068_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/wps.20038","article-title":"The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons","volume":"12","author":"Cuijpers","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jbtep.2004.04.006","article-title":"Elucidating the mechanism of uncertainty and doubt in obsessive-compulsive checkers","volume":"35","author":"Dar","year":"2004","journal-title":"J. Behav. Ther. Exp. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v60n0805","article-title":"Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder","volume":"60","author":"Davidson","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/da.10146","article-title":"Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study","volume":"19","author":"Davidson","year":"2004","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jad.2017.04.068_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/archpsyc.58.5.485","article-title":"Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder","volume":"58","author":"Davidson","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/01.jcp.0000106222.36344.96","article-title":"Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder","volume":"24","author":"Davidson","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.04.068_bib22","doi-asserted-by":"crossref","first-page":"c4737","DOI":"10.1136\/bmj.c4737","article-title":"Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials","volume":"341","author":"Eyding","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2017.04.068_bib23","series-title":"Exposure and Response (Ritual) Prevention for Obsessive Compulsive Disorder: Therapist Guide","author":"Foa","year":"2012"},{"key":"10.1016\/j.jad.2017.04.068_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.psychres.2014.05.023","article-title":"Assessing blinding in trials of psychiatric disorders: a meta-analysis based on blinding index","volume":"219","author":"Freed","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2017.04.068_bib25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4088\/JCP.v68n0508","article-title":"Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a department of veterans affairs setting","volume":"68","author":"Friedman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10865-005-9040-5","article-title":"Expectations and placebo response: a laboratory investigation into the role of somatic focus","volume":"29","author":"Geers","year":"2006","journal-title":"J. Behav. Med."},{"key":"10.1016\/j.jad.2017.04.068_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jad.2004.11.011","article-title":"Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials","volume":"87","author":"Goodman","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2017.04.068_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004850-199603000-00003","article-title":"Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial","volume":"11","author":"Goodman","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.04.068_bib29","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-brown obsessive compulsive scale. I. development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archpsyc.1995.03950160039008","article-title":"Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder","volume":"52","author":"Greist","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.jad.2017.04.068_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/YIC.0b013e32807fb1b2","article-title":"Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial","volume":"22","author":"Hartford","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.04.068_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jad.2015.03.021","article-title":"Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials","volume":"180","author":"Hayasaka","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2017.04.068_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3102\/10769986006002107","article-title":"Distribution theory for Glass's estimator of effect sizes and related estimators","volume":"6","author":"Hedges","year":"1981","journal-title":"J. Educ. Behav. Stat."},{"key":"10.1016\/j.jad.2017.04.068_bib35","series-title":"Statistical Methods for Meta-Analysis","author":"Hedges","year":"1985"},{"key":"10.1016\/j.jad.2017.04.068_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S0033291798007879","article-title":"Psychometric properties of the Liebowitz Social Anxiety Scale","volume":"29","author":"Heimberg","year":"1999","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2017.04.068_bib37","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.jad.2017.04.068_bib38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2017.04.068_bib39","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4088\/JCP.v64n0919","article-title":"Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine","volume":"64","author":"Hollander","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib40","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4088\/JCP.v64n0604","article-title":"A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder","volume":"64","author":"Hollander","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0005-7967(02)00097-9","article-title":"Phenomenological validity of an OCD-memory model and the remember\/know distinction","volume":"41","author":"van den Hout","year":"2003","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.jad.2017.04.068_bib42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0005-7967(02)00012-8","article-title":"Repeated checking causes memory distrust","volume":"41","author":"van den Hout","year":"2003","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.jad.2017.04.068_bib43","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1176\/appi.ajp.161.8.1485","article-title":"Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder","volume":"161","author":"Huppert","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib44","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib45","doi-asserted-by":"crossref","first-page":"e41778","DOI":"10.1371\/journal.pone.0041778","article-title":"A systematic review of comparative efficacy of treatments and controls for depression","volume":"7","author":"Khan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2017.04.068_bib46","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1017\/S0033291704003873","article-title":"Magnitude of placebo response and drug-placebo differences across psychiatric disorders","volume":"35","author":"Khan","year":"2005","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2017.04.068_bib47","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0006-3223(00)00832-5","article-title":"Are drug and placebo effects in depression additive?","volume":"47","author":"Kirsch","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib48","first-page":"100","article-title":"Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians","volume":"9","author":"Koponen","year":"2007","journal-title":"Prim Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00004714-199904000-00013","article-title":"Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder","volume":"19","author":"Kronig","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.04.068_bib50","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archpsyc.56.10.921","article-title":"The structure of common mental disorders","volume":"56","author":"Krueger","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib51","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1371\/journal.pmed.0020392","article-title":"Serotonin and depression: a disconnect between the advertisements and the scientific literature","volume":"2","author":"Lacasse","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.jad.2017.04.068_bib52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0447.1997.tb00388.x","article-title":"A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative paroxetine panic study investigators","volume":"95","author":"Lecrubier","year":"1997","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2017.04.068_bib53","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4088\/JCP.v65n0213","article-title":"Controlled-release paroxetine in the treatment of patients with social anxiety disorder","volume":"65","author":"Lepola","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib54","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4088\/JCP.08m04238","article-title":"A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder","volume":"70","author":"Liebowitz","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib55","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.v66n0213","article-title":"A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder","volume":"66","author":"Liebowitz","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib56","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4088\/JCP.v63n0113","article-title":"A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder","volume":"63","author":"Liebowitz","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib57","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4088\/JCP.v64n0708","article-title":"Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study","volume":"64","author":"Liebowitz","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib58","series-title":"Practical Meta-Analysis","author":"Lipsey","year":"2001"},{"key":"10.1016\/j.jad.2017.04.068_bib59","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1176\/appi.ajp.158.12.1982","article-title":"Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study","volume":"158","author":"Marshall","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1192\/bjp.172.3.227","article-title":"Meta-analysis of trials comparing antidepressants with active placebos","volume":"172","author":"Moncrieff","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib61","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0924-977X(93)90266-O","article-title":"A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD study group","volume":"3","author":"Montgomery","year":"1993","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.04.068_bib62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.psychres.2008.09.003","article-title":"Perseveration and not strategic deficits underlie delayed alternation impairment in obsessive-compulsive disorder (OCD)","volume":"170","author":"Moritz","year":"2009","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2017.04.068_bib63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S0033291708003401","article-title":"Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial","volume":"39","author":"Nicolini","year":"2009","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2017.04.068_bib64","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0005-7967(95)00042-V","article-title":"Inference processes in obsessive-compulsive disorder: some clinical observations","volume":"33","author":"O'Connor","year":"1995","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.jad.2017.04.068_bib65","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1192\/bjp.167.3.374","article-title":"Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study","volume":"167","author":"Oehrberg","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib66","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1176\/appi.ajp.2009.09060820","article-title":"Assuring that double-blind is blind","volume":"167","author":"Perlis","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib67","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1176\/ajp.155.9.1189","article-title":"Sertraline in the treatment of panic disorder: a double-blind multicenter trial","volume":"155","author":"Pohl","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib68","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archpsyc.55.11.1010","article-title":"Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial","volume":"55","author":"Pollack","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib69","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4088\/JCP.v62n0508","article-title":"Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial","volume":"62","author":"Pollack","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20218","article-title":"A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder","volume":"24","author":"Pollack","year":"2007","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2017.04.068_bib71","unstructured":"R Core Team, 2014. R: A Language and Environment for Statistical Computing. Vienna, Austria. From \u3008http:\/\/www.r-project.org\/\u3009."},{"key":"10.1016\/j.jad.2017.04.068_bib72","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0005-7967(97)00040-5","article-title":"A cognitive theory of obsessions","volume":"35","author":"Rachman","year":"1997","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.jad.2017.04.068_bib73","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.jcp.0000138764.31106.60","article-title":"A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder","volume":"24","author":"Rickels","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.04.068_bib74","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.157.6.968","article-title":"Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder","volume":"157","author":"Rickels","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib75","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.160.4.749","article-title":"Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study","volume":"160","author":"Rickels","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tics.2011.11.009","article-title":"Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry","volume":"16","author":"Robbins","year":"2012","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.jad.2017.04.068_bib77","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jamapsychiatry.2015.15","article-title":"Reporting bias in clinical trials investigating the efficacy of second-generation antidepressants in the treatment of anxiety disorders: a report of 2 meta-analyses","volume":"72","author":"Roest","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib78","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/da.20271","article-title":"Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial","volume":"25","author":"Rynn","year":"2008","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2017.04.068_bib79","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4088\/JCP.v66n0105","article-title":"Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder","volume":"66","author":"Sheehan","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1037\/0022-006X.75.1.85","article-title":"Fluoxetine, smoking, and history of major depression: a randomized controlled trial","volume":"75","author":"Spring","year":"2007","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.jad.2017.04.068_bib81","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","article-title":"Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial","volume":"280","author":"Stein","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2017.04.068_bib82","doi-asserted-by":"crossref","first-page":"e106337","DOI":"10.1371\/journal.pone.0106337","article-title":"The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton rating scales","volume":"9","author":"Sugarman","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2017.04.068_bib83","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/jclp.20080","article-title":"Understanding and treating incompleteness in obsessive-compulsive disorder","volume":"60","author":"Summerfeldt","year":"2004","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.jad.2017.04.068_bib84","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1037\/0033-295X.111.1.111","article-title":"Obsessive-compulsive disorder as a disturbance of security motivation","volume":"111","author":"Szechtman","year":"2004","journal-title":"Psychol. Rev."},{"key":"10.1016\/j.jad.2017.04.068_bib85","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0005-7967(00)00064-4","article-title":"Memory and memory confidence in obsessive-compulsive disorder","volume":"39","author":"Tolin","year":"2001","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.jad.2017.04.068_bib86","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archpsyc.1994.03950070051010","article-title":"A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder","volume":"51","author":"Tollefson","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib87","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4088\/JCP.v62n1105","article-title":"Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial","volume":"62","author":"Tucker","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib88","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy","volume":"358","author":"Turner","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2017.04.068_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.jad.2017.04.068_bib90","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1192\/bjp.bp.115.173450","article-title":"Influence of baseline severity on antidepressant efficacy for anxiety disorders: meta-analysis and meta-regression","volume":"208","author":"de Vries","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.068_bib91","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.janxdis.2007.02.009","article-title":"'I wash until it feels right' the phenomenology of stopping criteria in obsessive-compulsive washing","volume":"22","author":"Wahl","year":"2008","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.jad.2017.04.068_bib92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.jcp.0000104906.75206.8b","article-title":"A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder","volume":"24","author":"Westenberg","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.04.068_bib93","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000379756","article-title":"Therapeutic alliance in antidepressant treatment: cause or effect of symptomatic levels?","volume":"84","author":"Zilcha-Mano","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2017.04.068_bib94","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1192\/bjp.169.4.468","article-title":"Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD paroxetine study investigators","volume":"169","author":"Zohar","year":"1996","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032717303051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032717303051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:20:25Z","timestamp":1759022425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032717303051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":94,"alternative-id":["S0165032717303051"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2017.04.068","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2017.04.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}